A13-Personalized Oncology
Oncology / IBS-A13 / Consolidated
Research group made up of medical oncologists, biologists, pharmacists and psycho-oncologists whose main objective is to study resistance mechanisms, as well as to identify prognostic and predictive factors of response to applied oncological treatments that can help establish personalized treatments, minimizing secondary toxicity. derives from them. To do this, a study of response and survival predictor genes, studies of QT resistance genes and a study of the methylation profile as a biomarker and prognostic factor in cancer are fundamentally performed.
Research lines
- To study the methylation profile and its role as a prognostic and predictive biomarker in cancer
- Identify prognostic and predictive factors of response
- Mechanisms of resistance to cancer treatments
NATALIA LUQUE CARO
ALEJANDRO PRADOS MARTIN
FERNANDO GALVEZ MONTOSA
MARIA PADILLA VICO
RAFAEL AVALOS IVORY
SONIA PERALES ROMERO
JOSE PEDRO CARRASCOSA DE LA BLANCA
CRISTINA ALBA TORRES
JOAQUINA MARTINEZ GALAN
ELIZABETH MAZA SERRANO
LUCIA OCHOA VALLEJO
PEDRO JOSE REAL LUNA
ISABEL RODRIGUEZ GONZALEZ
JULIA RUIZ VOZMEDIANO
CARMEN SANCHEZ TORO
CAROLINA TORRES PEARLS
JAVIER VALDIVIA BAUTISTA
VICTOR AMEZCUA HERNANDEZ
LUCIA CASTLE PORTELLANO
VERONICA COUNT HERRERO
JUAN RAMON DELGADO PEREZ
JAVIER GARCIA GARCIA
ROSA MARIA GARRIDO PEREZ
ENCARNA GONZALEZ FLORES
PILAR GUTIERREZ PASTOR
RACHEL LUQUE CARO
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
ANNALS OF ONCOLOGY, 2024;
FI: 56,7; D1
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
EUROPEAN UROLOGY ONCOLOGY, 2024;
FI: 8,3; D1
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
EUROPEAN UROLOGY ONCOLOGY, 2024;
FI: 8,3; D1
Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024;
FI: 4,9; Q1
Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial
ESMO OPEN, 2024;
FI: 7,1; Q1
Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients
PHARMACEUTICS, 2023;
FI: 5,4; Q1
Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C
MOLECULAR THERAPY-NUCLEIC ACIDS, 2023;
FI: 8,8; Q1
Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review
CANCER, 2023;
FI: 5,2; Q2
Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023;
FI: 3; Q3
Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis
NMR IN BIOMEDICINE, 2023;
FI: 2,9; Q3
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior
THERANOSTICS, 2022;
FI: 11,6; D1
Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia.
FRONTIERS IN ENDOCRINOLOGY, 2022;
FI: 6,055; Q1
Generation of a H9 Clonal Cell Line With Inducible Expression of NUP98-KDM5A Fusion Gene in the AAVS1 Safe Harbor Locus
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022;
FI: 6,081; Q1
Upfront primary tumor resection and survival in synchronous metastatic colorectal cancer according to primary tumor location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
EJSO, 2022;
FI: 4,037; Q3
Biomarkers associated with survival and favorable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single center experience
SPANISH JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGE, 2022;
FI: 1,247; Q4
Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer.
JOURNAL OF CLINICAL MEDICINE, 2021;
FI: 4,242; Q1
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation.
CANCER, 2021;
FI: 6,639; Q1
Deep Phenotypic Characterization of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream).
CANCER, 2021;
FI: 6,639; Q1
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
CANCER, 2021;
FI: 6,639; Q1
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
DRUGS & AGING, 2021;
FI: 3,923; Q2
Dissociable Effects of Executive Load on Perceived Exertion and Emotional Valence during Submaximal Cycling
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020;
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer
EUROPEAN UROLOGY, 2020;
FI: 18,728; D1
Facile synthesis of B / gC (3) N (4) composite materials for the continuous-flow selective photo-production of acetone
GREEN CHEMISTRY, 2020;
FI: 9,48; D1
Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics
CANCER, 2020;
FI: 6,126; Q1
Improving Electrochemical Hydrogen Evolution of Ag @ CN Nanocomposites by Synergistic Effects with alpha-Rich Proteins
ACS APPLIED MATERIALS & INTERFACES, 2020;
FI: 8,758; Q1
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer
EUROPEAN JOURNAL OF CANCER CARE, 2019;
FI: 2,421; D1
Phase I / II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
JOURNAL OF CLINICAL ONCOLOGY, 2019;
FI: 28,349; D1
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
BRITISH JOURNAL OF CANCER, 2019;
FI: 5,416; Q1
Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients.
SCIENTIFIC REPORTS, 2019;
FI: 4,011; Q1
Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer.
SCIENTIFIC REPORTS, 2019;
FI: 4,011; Q1
Chemical composition of the edible flowers, pansy (Viola wittrockiana) and snapdragon (Antirrhinum majus) as new sources of bioactive compounds
FOOD CHEMISTRY, 2018;
FI: 4,946; D1
Activating Transcription Factor 4 Modulates TGF beta-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2 / 3/4 and mTORC2 Signaling
CLINICAL CANCER RESEARCH, 2018;
FI: 10,199; D1
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group
AMERICAN JOURNAL OF HEMATOLOGY, 2018;
FI: 5,303; Q1
Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer
INTERNATIONAL JOURNAL OF CANCER, 2018;
FI: 7,36; Q1
Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018;
FI: 4,302; Q1
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017;
FI: 5,133; D1
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
NEURO-ONCOLOGY, 2017;
FI: 7,786; D1
Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1)
ORAL ONCOLOGY, 2017;
FI: 4,794; D1
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group
EUROPEAN JOURNAL OF CANCER, 2017;
FI: 6,029; Q1
Pancreatic ductal adenocarcinoma: metastatic disease
CLINICAL & TRANSLATIONAL ONCOLOGY, 2017;
FI: 2,353; Q3
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03 / VECTITAX study
ORAL ONCOLOGY, 2016;
FI: 4,286; D1
Pharmacogenetic predictors of toxicity to platinum-based chemotherapy in non-small cell lung cancer patients.
PHARMACOLOGICAL RESEARCH, 2016;
FI: 4,816; Q1
Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients
PLOSONE, 2016;
FI: 3,057; Q1
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
JOURNAL OF NEURO-ONCOLOGY, 2016;
FI: 2,754; Q2
SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma
PHARMACOGENOMICS, 2016;
FI: 2,71; Q2
Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly (butylcyanoacrylate) nanoparticles
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015;
FI: 4,383; Q1
Totally endoscopic surgery on diastasis recti associated with midline hernias. The advantages of a minimally invasive approach. prospective cohort study
HERNIA, 2015;
FI: 2,05; Q2
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). DTT 08-02
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015;
FI: 2,769; Q2
The Potential Role of the Glycoprotein Osteoactivin / Glycoprotein Nonmetastatic Melanoma Protein B in Pancreatic Cancer
PANCREAS, 2015;
FI: 2,959; Q2
Prognosis Relevance of Serum Cytokines in Pancreatic Cancer
BIOMED RESEARCH INTERNATIONAL, 2015;
FI: 1,579; Q3
Platelet- and tumor-derived extracellular vesicles (EVs) as drivers of carcinogenesis and metastasis in pancreatic cancer (EVprofiler).
Funder: STATE RESEARCH AGENCY - PRTR
File number: PID2023-152099OB-I00
Execution time: 01/09/2024 - 31/08/2028
IP: PEDRO JOSE REAL LUNA
Development of Gene-Cell Therapy strategies for the treatment of Bernard-Soulier Syndrome.
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI16 / 01340
Execution time: 01/01/2017 - 31/12/2020
IP: PEDRO JOSE REAL LUNA
New Animal Models and New Therapeutic Tools for the Cure of Bernard-Soulier Syndrome.
Funder: UNIVERSITY OF GRANADA
File number: B-CTS-676-UGR20
Execution time: 01/07/2021 - 30/06/2023
IP: PEDRO JOSE REAL LUNA
Development and clinical validation of an interconnected graphene-based biosensor platform for the early diagnosis of sepsis at the point of care and the optimization of its clinical management
Funder: STATE RESEARCH AGENCY
File number: CPP2022-009952
Execution time: 01/11/2023 - 31/12/2025
IP: LUCIA CASTILLO PORTELLANO
New animal models and therapeutic tools to cure Bernard-Soulier Syndrome.
Funder: STATE RESEARCH AGENCY
File number: PID2019-110153RB-I00
Execution time: 01/06/2020 - 31/05/2023
IP: PEDRO JOSE REAL LUNA
Development of Bioinformatic Models Based on the Gene Expression Profile in Peripheral Blood With Diagnostic Value in Pancreatic Adenocarcinoma
Funder: COUNCIL OF HEALTH
File number: PC-0498-2017
Execution time: 01/01/2018 - 31/12/2020
PI: JOAQUINA MARTINEZ GALAN
OncoSil clinical pharmacovigilance registry for pancreatic cancer. Medical Device: OncoSil System™.
Funder: ONCOSIL MEDICAL LTD
Type of test: CLINICAL RESEARCH WITH MEDICAL DEVICES
Execution time: 13/12/24 - 31/12/30
PI: JOAQUINA MARTINEZ GALAN
Observational study of the effectiveness of medications funded by the National Health System for genitourinary tumors.
Funder: MFAR CLINICAL RESEARCH SL
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 10/05/2024 - 30/04/2034
PI: RAQUEL LUQUE CARO
A randomized, open-label, active-controlled, multicenter phase 3 study of sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb in previously untreated subjects with metastatic colorectal cancer with the p.G12C KRAS mutation (CodeBreaK 301).
Financier: AMGEN SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 09/08/2024 - 30/11/2031
PI: ENCARNA GONZALEZ FLORES
A phase Ib/III, open-label, randomized trial of capivasertib plus CDK4/6 inhibitors and fulvestrant versus CDK4/6 inhibitors and fulvestrant in hormone receptor-positive and human epidermal growth factor receptor 2-negative, locally advanced, unresectable, or metastatic breast cancer (CAPItello-292)
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 22/11/2024 - 30/09/2029
PI: ENCARNA GONZALEZ FLORES
A phase III, randomized, multicenter study to evaluate the efficacy and safety of INT230-6 (SHAO, vinblastine, cisplatin) administered intratumorally compared with standard US therapy in adult participants with locally recurrent, inoperable, or metastatic soft tissue sarcomas (INVINCIBLE-3 TRIAL).
Funder: INTENSITY THERAPEUTICS, INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 30/09/2024 - 30/12/2027
IP: LUCIA CASTILLO PORTELLANO
REFRaME-O1: A Phase II/III, open-label study to evaluate the efficacy and safety of luveltamab tazevibulin (STRO-002) compared with investigator's choice (IE) chemotherapy in women with platinum-resistant recurrent epithelial ovarian carcinoma (including fallopian tube and primary peritoneal cancer) with folate receptor alpha (FOLR1) expression
Funder: PREMIER RESEARCH GROUP SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 25/09/2024 - 30/05/2027
IP: LUCIA CASTILLO PORTELLANO
Phase Ib/II multicohort trial of different regimens of PM14 as monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors
Funder: GEIS - SPANISH SARCOMA RESEARCH GROUP
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/09/2024 - 30/09/2028
IP: LUCIA CASTILLO PORTELLANO
An open-label, interventional, phase Ib/II safety and efficacy study to investigate the tolerability, PK, and antitumor activity of Vepdegestrant (ARV-471/PF-07850327), an oral proteolysis-targeted chimera, in combination with PF-07220060 in participants 18 years of age and older with ER+/Her2- advanced or metastatic breast cancer
Funder: PPD Research Services LLC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 04/04/2024 - 30/08/2026
PI: ENCARNA GONZALEZ FLORES
A prospective, multicenter, open-label clinical trial to evaluate the efficacy and safety of TheraSphere™ followed by durvalumab (Imfinzi®) with tremelimumab (Imjudo®) for hepatocellular carcinoma (HCC). ROWAN
Financier: BOSTON SCIENTIFIC INTERNATIONAL SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 17/01/2024 - 30/08/2027
PI: JOAQUINA MARTINEZ GALAN
A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 and Pembrolizumab in Patients With Unresectable Recurrent or Metastatic HPV16-positive Head-Neck Squamous Cell Carcinoma
Funder: PREMIER RESEARCH GROUP SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 12/01/2024 - 30/09/2025
PI: JOAQUINA MARTINEZ GALAN
Phase Ib dose-finding study evaluating the safety and activity of [177Lu]Lu-NeoB in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma and as monotherapy in recurrent glioblastoma.
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 29/01/2024 - 30/12/2025
PI: RAQUEL LUQUE CARO
Avelumab in the treatment of urothelial cancer in the real world – The AVENUE non-interventional study
Funder: MERCKLE GMBH
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 12/06/2023 - 30/08/2027
PI: RAQUEL LUQUE CARO
Evaluation of the efficacy and safety of avapritnib in a real-life series of patients diagnosed with gastrointestinal stromal tumor (GIST), with PDGFRA D842V mutation with locally advanced or metastatic disease, treated with avapritinib
Funder: PRIVATE FOUNDATION VALL D'HEBRON ONCOLOGY RESEARCH INSTITUTE
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 26/09/2023 - 30/04/2024
PI: JUAN RAMON DELGADO PEREZ
Real-world treatment and clinical outcomes in patients with stage I-III lung cancer in Spain: an observational, retrospective, multicenter study (REALUNG study).
Financier: BRISTOL-MYERS SQUIBB, SAU
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 07/02/2023 - 30/07/2023
PI: JAVIER VALDIVIA BAUTISTA
Ambispective study of patients with triple negative breast cancer treated with sacituzumab Govitecan in southern Spain
Funder: SEVILLE HEALTH RESEARCH MANAGEMENT FOUNDATION
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 29/09/2023 - 30/06/2024
PI: ENCARNA GONZALEZ FLORES
A phase IIIb, multicenter, global, interventional, open-label study of trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody-drug conjugate (ADC), in subjects with unresectable and/or metastatic HER2-low or immunohistochemical (IHC) HER2 0 breast cancer (BC)
Funder: DAIICHI-SANKYO, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 21/11/2023 - 20/05/2028
PI: ENCARNA GONZALEZ FLORES
Phase III trial of Fianlimab (Anti-Lag-3) and Cemiplimab compared with Pembrolizumab as adjuvant therapy in patients with completely resected high-risk melanoma
Funder: REGENERON PHARMACEUTICALS, INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 07/06/2023 - 30/09/2030
PI: JAVIER VALDIVIA BAUTISTA
A phase 3, randomized, double-blind study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05)
Funder: SEAGEN INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/06/2023 - 30/08/2027
PI: ENCARNA GONZALEZ FLORES
A phase III, multicenter, randomized, placebo-controlled, double-blind trial of selinexor maintenance treatment after systemic therapy in patients with advanced or recurrent untreated endometrial carcinoma
Funder: KARYOPHARM THERAPEUTICS, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 20/10/2023 - 30/06/2025
IP: LUCIA CASTILLO PORTELLANO
A Phase 3, Randomized, Open-Label, Multicenter Study of ARV-471 (PF-07850327) Versus Fulvestrant in Participants With Estrogen Receptor-Positive, HER2-Naive Advanced Breast Cancer Whose Disease Has Progressed After Previous Therapy
Funder: PFIZER INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 27/04/2023 - 30/01/2028
PI: VERONICA CONDE HERRERO
Phase 3, randomized, open-label, multicenter study of ARV-471 (PF-07850327) plus palbociclib compared with letrozole plus palbociclib for the treatment of participants with estrogen receptor-positive, her2-negative breast cancer who do not have
Funder: PFIZER INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 04/07/2023 - 30/07/2026
PI: ENCARNA GONZALEZ FLORES
Phase III, open-label, randomized study to evaluate the efficacy and safety of long-term treatment with camizestrant (AZD9833, a new-generation oral, selective estrogen receptor degrader) versus standard endocrine therapy
Funder: ASTRAZENECA AB
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 09/06/2023 - 30/05/2037
PI: VERONICA CONDE HERRERO
Phase II, open-label, single-arm, multinational, multicenter study to evaluate the efficacy and safety of 5 years of treatment with osimertinib in participants with Stage II-IIIB non-small cell lung carcinoma with a receptor mutation.
Funder: ASTRAZENECA AB
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 31/01/2023 - 30/04/2029
PI: JAVIER VALDIVIA BAUTISTA
Open-label, multicenter phase I/II study of the genetic vaccine Nous-209 for the treatment of solid tumors with microsatellite instability
Funder: NOUSCOM SRL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/07/2023 - 30/01/2026
PI: ENCARNA GONZALEZ FLORES
Open-label, randomized, perioperative phase III study of Dostarlimab monotherapy versus standard of care in patients with resectable colon cancer with loss of base-pair repair (dMMR)/microarray instability.
Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/09/2023 - 30/11/2031
PI: ENCARNA GONZALEZ FLORES
Phase II, single-arm, open-label study of dostarlimab monotherapy in patients with previously untreated locally advanced stage II/III dMMR/MSI-H rectal cancer.
Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 23/02/2023 - 30/09/2029
PI: ENCARNA GONZALEZ FLORES
Open-label, randomized, non-comparative Phase 2 study of ARV-471 or anastrozole in postmenopausal women with ER+/HER2– breast cancer in the neoadjuvant setting. TRIO048
Financier: ARVINAS ESTROGEN RECEPTOR INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/02/2023 - 30/06/2024
PI: ENCARNA GONZALEZ FLORES
An open-label dosimetry, biodistribution, tolerability, and safety study of lutetium (177Lu) vipivotide tetraxetane in participants with progressive metastatic castration-resistant PSMA-positive prostate cancer and severe renal impairment, mo
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 18/09/2023 - 30/05/2026
PI: RAQUEL LUQUE CARO
Multicenter, international, randomized, prospective, open-label, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetane (AAA617) monotherapy and lutetium [177Lu] vipivotide tetraxetane (AAA617) in combination with v inhibitors
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 24/10/2023 - 30/11/2028
PI: RAQUEL LUQUE CARO
Retrospective epidemiological study of clinical history review on patient characteristics, treatment patterns and resource use in patients with locally advanced (La) or metastatic (mUC) urothelial cancer in Spain.
Funder: ASTELLAS PHARMA EUROPE LTD
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 03/02/2022 - 30/08/2022
PI: RAQUEL LUQUE CARO
Retrospective study of efficacy and tolerability of liposomal irinotecan plus 5fu/lv in the treatment of pancreatic adenocarcinoma.
Funder: HM HOSPITALES RESEARCH FOUNDATION
Test type: REST OF EEOO WITH MEDICATIONS
Execution time: 24/05/2022 - 30/08/2022
PI: JOAQUINA MARTINEZ GALAN
Phase II clinical trial of the combination of palbociclib, trastuzumab, and endocrine therapy, in patients with previously treated HER2-positive locally advanced or metastatic breast cancer. PATRICIAII. GEICAM/2018-07
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 09/03/2022 - 30/06/2024
PI: ENCARNA GONZALEZ FLORES
Phase III Study of Fianlimab (REGN3767, anti LAG-3) + Cemiplimab Compared to Pembrolizumab in Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Melanoma
Funder: REGENERON PHARMACEUTICALS, INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 21/09/2022 - 30/09/2030
PI: JAVIER VALDIVIA BAUTISTA
Phase Ib, Open-Label, Multicenter, Intra-Patient Dose Escalation Clinical Trial to Evaluate the Safety Profile of the Combination of Tilray FS Oral Solution T10:C10 (THC + CBD) with Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Funder: GEINO (GRUPO ESPAÑOL DE NEURONCOLOGI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 04/04/2022 - 30/12/2023
PI: RAQUEL LUQUE CARO
Multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, for 52 weeks, in women with hormone receptor-positive or high-risk breast cancer to develop it.
Funder: BAYER AG
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 06/10/2022 - 07/12/2024
PI: ENCARNA GONZALEZ FLORES
Phase II, open-label, multicenter trial to evaluate the efficacy and safety of nal-IRI in patients with HER2-negative breast cancer with progressing brain metastases. PHENOMENAL
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/11/2022 - 30/04/2024
PI: ENCARNA GONZALEZ FLORES
Phase 2 trial of standard neoadjuvant chemotherapy or patritumab deruxtecan (U3-1402; HER3-DXd) with or without endocrine therapy for high-risk HR+/HER2- breast cancer: VALENTINE Trial.
Funder: SOLTI
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 29/11/2022 - 30/10/2029
PI: ENCARNA GONZALEZ FLORES
Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human L19TNF antibody-cytokine fusion protein versus doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma. FIBROSARC
Funder: PHILOGEN SPA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 23/05/2022 - 30/11/2028
IP: LUCIA CASTILLO PORTELLANO
Phase III, multicenter, randomized, open-label, endpoint-blind study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer-associated VTE gastrointestinal (GI) or genitourinary (GU) (Magnolia)
Funder: ANTHOS THERAPEUTICS
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/04/2022 - 11/08/2024
PI: RAQUEL LUQUE CARO
Open-label, multinational, multicenter phase IIIb/IV study of trastuzumab deruxtecan in patients with or without initial brain metastasis with previously treated HER2-positive advanced/metastatic breast cancer (DESTINY-Breast12).
Funder: ASTRAZENECA AB
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 24/06/2022 - 30/03/2024
PI: ENCARNA GONZALEZ FLORES
Phase III, multicenter, randomized, open-label, endpoint-blind study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer-associated VTE. ASTER
Funder: ANTHOS THERAPEUTICS
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/04/2022 - 06/05/2024
PI: RAQUEL LUQUE CARO
Phase II, open-label, multicenter study of combination immunotherapy with PDS0101 (R-DOTAP [Versamune®] + HPVmix) and pembrolizumab (KEYTRUDA®) in subjects with recurrent and/or metastatic head and neck cancer and HIV infection. high-risk human papilloma 16 (HPV16)
Funder: PDS BIOTECHNOLOGY CORPORATION
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 29/04/2022 - 30/09/2024
PI: JOAQUINA MARTINEZ GALAN
Phase III study of Sotorasib + Panitumumab versus Trifluridine and Tipiracil or Regorafenib in patients with previously treated KRASG12C metastatic colorectal cancer (CodeBreak 300)
Financier: AMGEN SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 15/03/2022 - 30/09/2024
PI: ENCARNA GONZALEZ FLORES
Phase Ib Dose-Finding Study Evaluating the Safety and Activity of [177Lu]Lu-DOTATATE in Combination With Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma and as Monotherapy in Recurrent Glioblastoma
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 10/03/2022 - 30/05/2025
PI: RAQUEL LUQUE CARO
VOLUME-PRO niVOLUMab in the real world in patients with squamous cell carcinoma of the head & neck (SCCHN) – Patient Reported Outcomes (PRO). BMS-NIV-2020-01
Funder: BRISTOL-MYERS SQUIBB COMPANY
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 26/04/2021 - 30/12/2022
PI: JOAQUINA MARTINEZ GALAN
European treatment patterns and outcomes associated with first-line CDK4/6 inhibitor and hormonal therapies evaluated in a non-interventional real-world study (EUCHARIS)
Funder: PFIZER INC
Type of test: REST OF OBSERVATIONAL STUDIES WITH MEDICINES
Execution time: 20/10/2021 - 30/12/2022
PI: ENCARNA GONZALEZ FLORES
Frailty screening tools in elderly patients with metastatic castration-resistant prostate cancer treated with docetaxel and without prior chemotherapy. FRAGDOC
Funder: GRUPO ESPAÑOL ONCOLOGIA GENITOURINARIA (SOGUG)
Type of test: OBSERVATIONAL STUDY WITH PROSPECTIVE FOLLOW-UP MEDICATIONS
Execution time: 03/09/2021 - 30/06/2024
PI: RAQUEL LUQUE CARO
RE-SEARCH study: dosing regimens with regorafenib in clinical practice in Spain: a retrospective study. 21749 (RESEARCH)
Financer: BAYER HISPANIA SL
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 16/07/2021 - 30/07/2022
PI: ENCARNA GONZALEZ FLORES
Retrospective study of the use of cetuximab and paclitaxel in the first-line treatment of head and neck and/or metastatic squamous cell carcinoma. REAL LIFE DATA. TTC-CET-2020-01
Funder: SPANISH GROUP HEAD TUMOR TREATMENT
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 18/01/2021 - 30/12/2021
PI: JOAQUINA MARTINEZ GALAN
Retrospective observational study to evaluate the effectiveness, safety and tolerability in real life in Spain of encorafenib plus cetuximab (CE) in the second-line treatment of metastatic colorectal cancer with BRAFV600E mutation. CONFIDENCE
Funding: DIGESTIVE TUMORS TREATMENT GROUP
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 30/11/2021 - 30/04/2022
PI: ENCARNA GONZALEZ FLORES
Observational analysis of treatment with palbociclib in patients with rh+/her2- locally advanced and/or metastatic breast cancer in first-line treatment within routine clinical practice. PALBOCICLIB 2. PALBOSPAIN
Financer: FOUNDATION FOR BIOMEDICAL RESEARCH OF THE SAN CARLOS CLINICAL HOSPITAL
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 27/09/2021 - 30/06/2023
PI: ENCARNA GONZALEZ FLORES
PRESERVE 1: Phase III, randomized, double-blind study of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer.
Funder: G1 THERAPEUTICS
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 08/06/2021 - 03/05/2025
PI: ENCARNA GONZALEZ FLORES
Phase 3, randomized, double-blind study of adjuvant immunotherapy with Relatlimab and Nivolumab in fixed-dose combination versus Nivolumab monotherapy in patients with stage III-IV melanoma after complete resection
Funder: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 10/12/2021 - 30/12/2028
PI: JAVIER VALDIVIA BAUTISTA
Phase III, multicenter, open-label study of ribociclib compared to palbociclib in patients with hormone receptor-positive/HER2-negative/HER2-enriched advanced breast cancer – HARMONIA trial.
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 24/11/2021 - 28/02/2028
PI: VERONICA CONDE HERRERO
Continuation study in patients who have completed a previous oncology study with olaparib and who are considered by the investigator to clinically benefit from continuing treatment. ROSY-O
Funder: ASTRAZENECA AB
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 21/06/2021 - 30/09/2030
PI: ENCARNA GONZALEZ FLORES
Phase III, multicenter, double-blind, placebo-controlled clinical study comparing chemoimmunotherapy paclitaxel-carboplatin-oregovomab) versus chemotherapy (paclitaxel-carboplatin-placebo) in patients with epithelial carcinoma of the ovary
Funder: ONCOQUEST PHARMACEUTICALS INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 27/05/2021 - 30/12/2025
IP: LUCIA CASTILLO PORTELLANO
Phase III randomized trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in previously treated patients with HER2+ advanced breast cancer with PIK3CA mutation. “ALPHABET study”.
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 14/09/2021 - 30/05/2026
PI: ENCARNA GONZALEZ FLORES
Phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of the combination of capmainib (INC280) and spartalizumab (PDR001) versus capmayinib and placebo as first-line treatment in patients with cancer.
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 12/02/2021 - 30/01/2032
PI: JAVIER VALDIVIA BAUTISTA
Phase 2, randomized, open-label study of trilaciclib co-administered with first-line platinum-containing chemotherapy and avelumab maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma
Funder: G1 THERAPEUTICS
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 20/10/2021 - 30/10/2023
PI: RAQUEL LUQUE CARO
Open-label study with tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants with previously untreated, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with CEACAM5-positive tumors
Funder: SANOFI AVENTIS RECHERCHE & DEVELOPPEMENT
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 28/07/2021 - 28/02/2023
PI: JOAQUINA MARTINEZ GALAN
Retrospective registry of patients with HR + Her2-treated locally advanced / metastatic breast cancer in clinical practice in Andalusia
Funder: SOCIEDAD ANDALUZA DE ONCOLOGIA MEDICA
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 06/10/2020 - 30/07/2021
PI: ENCARNA GONZALEZ FLORES
Phase III, randomized, double-blind clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer, followed by adjuvant atezolizumab or placebo.
Funder: GERMAN BREAST GBG FORSCHUNGSGESELLSCHAFT GMBH
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 06/03/2020 - 30/09/2024
PI: VERONICA CONDE HERRERO
Single-arm phase IIIB trial of Durvalumab in combination with Platinum-Etoposide for patients with extended-stage small cell lung cancer who have not received treatment, reflecting real clinical practice in Spain (CANTABRICO).
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 18/11/2020 - 30/05/2022
PI: VICTOR AMEZCUA HERNANDEZ
Observational study to assess the absolute Burden Of hpv-related head and Neck cancers. The BROADEN Study
Funder: MERCK SHARP & DOHME DE ESPAÑA SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 30/10/2020 - 30/04/2021
PI: JOAQUINA MARTINEZ GALAN
VOLUME: niVOLUMab in real clinical practice in patients with squamous cell carcinoma of the head and neck (SCCC)
Funder: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 16/10/2020 - 31/07/2021
PI: JOAQUINA MARTINEZ GALAN
Multicenter, observational and retrospective study to evaluate the clinical management of patients newly diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC), and to characterize and describe how the procedure is carried out.
Funder: MERCK SHARP & DOHME DE ESPAÑA SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 04/02/2020 - 30/12/2020
PI: JAVIER VALDIVIA BAUTISTA
Randomized multicenter phase II clinical trial to evaluate the efficacy and safety of the combination of nivolumab and paclitaxel in the first line of treatment in patients with non-candidate recurrent or metastatic squamous cell carcinoma of the head and neck
Funder: SPANISH GROUP HEAD TUMOR TREATMENT
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 07/02/2020 - 30/09/2026
PI: JOAQUINA MARTINEZ GALAN
Phase III, open-label, randomized, multicenter study of injectable liposomal irinotecan, oxaliplatin, 5-fluorouracil / leucovorin versus nabpaclitaxel plus gemcitabine in patients who have not previously received chemotherapy for adenocarcin
Funder: IPSEN BIOSCIENCE, INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 18/03/2020 - 30/05/2022
PI: JOAQUINA MARTINEZ GALAN
A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)
Funder: GORTEC (GROUPE D'ONCOLOGIE READIOTHÉRAPIE TÊTE ET COU)
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 30/06/2020 - 31/07/2027
PI: JOAQUINA MARTINEZ GALAN
Phase II, randomized, open-label, global, multicenter study of MEDI4736 monotherapy, Tremelimumab monotherapy, and MEDI4736 in combination with Tremelimumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 15/12/2015 - 28/02/2018
PI: JOAQUINA MARTINEZ GALAN
Phase II clinical study of Durvalumab (MEDI4736) plus Tremalimumab for the treatment of patients with advanced neuroendocrine tumors of gastroenteropathic or pulmonary origin (DUNE)
Funder: GETNE (SPANISH GROUP OF NEUROENDOCRINE AND ENDOCRINE TUMORS)
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 23/03/2017 - 30/03/2019
PI: ENCARNA GONZALEZ FLORES
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumor, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer. CHESS
Funder: EUROPEAN THORACIC ONCOLOGY PLATFORM
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 20/11/2019 - 30/09/2022
PI: JAVIER VALDIVIA BAUTISTA
Phase IIB, randomized, multicenter clinical trial, continuation or non-continuation with 6 cycles of temozulomide after the first 6 cycles of standard first-line treatment in patients with glioblastoma
Funder: GEINO (GRUPO ESPAÑOL DE NEURONCOLOGI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 20/01/2017 - 31/12/2017
PI: CARMEN SANCHEZ TORO
Phase II study to evaluate the activity and safety of TH-302 in combination with subitinib for patients with previously untreated metastatic well or moderately differentiated pancreatic neuroendocrine tumors (pNET)
Funder: GRUPO ESPAÑOL DE TUMORES NEUROENDOCRINO (GETNE)
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 13/03/2015 - 30/10/2017
PI: ENCARNA GONZALEZ FLORES
Phase II multicenter clinical study of lurbinectedin (PM01183) in selected advanced solid tumors
Financier: PHARMA MAR, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 05/02/2018 - 30/11/2019
PI: JAVIER VALDIVIA BAUTISTA
Phase Ib / II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and head and neck squamous cell carcinoma expansion cohort (CCECC)
Financier: TRANSGENE SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 24/05/2019 - 30/12/2020
PI: JOAQUINA MARTINEZ GALAN
Randomized multicenter phase II pilot study to evaluate the efficacy and safety of treatment with FOLFIRI-aflibercept compared with an initial treatment with FOLFIRI-afliercept (for 6 cycles) followed by maintenance with 5FU-aflibercept in elderly patients with metastatic colorectal cancer (mCRC) after of failure of an oxaliplatin regimen
Funder: DIGESTIVE TUMOR TREATMENT GROUP (TTD)
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 21/06/2017 - 30/07/2021
PI: ENCARNA GONZALEZ FLORES
Phase I, open label, dose escalation with expansion study to evaluate the safety and tolerability of INC280 in patients with advanced solid tumors dependent on C-MET
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 09/12/2014 - 30/03/2016
PI: JUAN RAMON DELGADO PEREZ
Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC + CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Funder: GEINO (GRUPO ESPAÑOL DE NEURONCOLOGI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 10/08/2018 - 30/09/2020
PI: RAQUEL LUQUE CARO
Phase II, randomized, open-label and multicenter study to evaluate the effect of oral metronomic vinorelbine versus best supportive treatment as maintenance therapy after taxane-based first-line chemotherapy in patients with treatment-resistant HER-2 negative breast cancer. endocrine
Funder: FISABIO
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 17/01/2017 - 30/08/2020
PI: ENCARNA GONZALEZ FLORES
Phase 1b / 2, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of B-701 plus docetaxel compared to placebo plus docetaxel in the treatment of locally advanced or metastatic urothelial carcinoma in patients with relapse after treatment reference or who have not responded to this
Funder: BIOCLIN THERAPEUTICS INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 01/03/2018 - 31/12/2021
PI: RAQUEL LUQUE CARO
Open, multicenter clinical trial of nivolumab (BMS-936558) as monotherapy in subjects with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) who have received at least two previous lines of systemic treatment for the treatment of stage IIIb squamous cell NSCLC IV
Funder: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 08/04/2015 - 30/05/2021
PI: JAVIER VALDIVIA BAUTISTA
Global, Multicenter, Phase II Single-Arm Study of MEDI4736 Monotherapy Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Funder: ASTRAZENECA AB
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 30/04/2015 - 30/07/2017
PI: JOAQUINA MARTINEZ GALAN
